| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/19/2006 | WO2006005582A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005535A1 Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
| 01/19/2006 | WO2006005361A1 Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
| 01/19/2006 | WO2006005268A2 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 01/19/2006 | WO2005089285A3 Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
| 01/19/2006 | WO2005086947A3 Method for inhibiting immune complex formation in a subjetc |
| 01/19/2006 | WO2005071080A3 Modulation of glucocorticoid receptor expression |
| 01/19/2006 | WO2005037317A3 Mast cell-derived renin |
| 01/19/2006 | WO2004096841A8 Glut-1 as a receptor for htlv envelopes and its uses |
| 01/19/2006 | WO2004094620A3 Truncated baff receptors |
| 01/19/2006 | WO2004033643A3 Methods of use of a dna helicase in the diagnosis and treatment of colon and lung cancer |
| 01/19/2006 | WO2004028472A3 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
| 01/19/2006 | US20060015960 Production of heterologous proteins in avians |
| 01/19/2006 | US20060015954 GPR54 knock-out mammals and screening methods using them |
| 01/19/2006 | US20060015951 Proteins involved in the regulation of energy homeostasis |
| 01/19/2006 | US20060014934 Crystal structure of factor Vai and method for identifying blood factor Va modulators |
| 01/19/2006 | US20060014931 Novel promoter |
| 01/19/2006 | US20060014930 Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 01/19/2006 | US20060014929 Liquid phase peptide synthesis of KL-4 pulmonary surfactant |
| 01/19/2006 | US20060014928 Scorpion peptide as hypotensive agent |
| 01/19/2006 | US20060014927 Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use |
| 01/19/2006 | US20060014926 Human papillomavirus E6 and E7 polypeptides, mutant polypeptide retains 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7 |
| 01/19/2006 | US20060014773 ATP and/or creatine phosphate synthesis promoter, free radical scavenger, membrane function supporter, cortisol action down regulator and antiapoptotic agent; brain and neurological function support |
| 01/19/2006 | US20060014727 Angiogenic compounds and uses thereof |
| 01/19/2006 | US20060014720 Can be implanted for therapy of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor |
| 01/19/2006 | US20060014716 Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection |
| 01/19/2006 | US20060014712 Controlled delivery of therapeutic compounds |
| 01/19/2006 | US20060014701 Novel amide derivatives as growth hormone secretagogues |
| 01/19/2006 | US20060014700 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies |
| 01/19/2006 | US20060014699 Aqueous pharmaceutical formulaton comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism |
| 01/19/2006 | US20060014698 Nebulized pharmaceutical compositions for the treatment of bronchial disorders |
| 01/19/2006 | US20060014697 Pharmaceutical compositions comprised of amino acid, peptide, or oligopeptide attached to an active agent; when delivered at proper dosage composition provides therapeutic activity similar to that of parent active agent; when delivered at higher dose potential for overdose is reduced |
| 01/19/2006 | US20060014696 Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
| 01/19/2006 | US20060014694 Peptide purification |
| 01/19/2006 | US20060014693 Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity |
| 01/19/2006 | US20060014692 Methods of using non-human animal Apoliprotein A-I protein |
| 01/19/2006 | US20060014691 Mechanically activated channel blocker |
| 01/19/2006 | US20060014690 EGFR ligand polypeptide variants; inhibition of the receptor's kinase activation activity and subsequently, cell proliferation |
| 01/19/2006 | US20060014689 And the C-natriuretic peptide hormone; antiproliferative agents; pancreatic cancer |
| 01/19/2006 | US20060014688 Methods of inhibiting tumor cell proliferation |
| 01/19/2006 | US20060014687 Bone delivery conjugates and method of using same to target proteins to bone |
| 01/19/2006 | US20060014686 Screening for agents that modulate the activity or expression of FOXM1; determining whether a subject has lung, colon, or breast cancer |
| 01/19/2006 | US20060014685 Treating a disease or condition associated with a disorder of glucose metabolism; diabetes mellitus of Type I or Type II, insulin resistance |
| 01/19/2006 | US20060014684 Novel uses of EGF |
| 01/19/2006 | US20060014683 Procoagulant protein comprising polypeptide with amino acid substitutions; resistant to activated protein C; von Willebrand factor binding site deleted and thrombin cleavage site is mutated; treating hemophilia |
| 01/19/2006 | US20060014682 Chemokine receptor antagonist peptide with a sequence homologous to SDF-1 wherein at least one amino acid at positions five to eight are substituted with proline; proliferative agents; self-regeneration of stem cells |
| 01/19/2006 | US20060014681 Three-dimensional structure of complement receptor type 2 and uses thereof |
| 01/19/2006 | US20060014680 Peptides of sequence of amino acids where one or more of the peptidyl [ C(O)NR ] linkages (bonds) have been replaced by a non-peptidyl linkage; IL-5 antagonists treating asthma |
| 01/19/2006 | US20060014679 Drug screening; diabetes, obesity, hyperlipemia, arteriosclerosis, hypertension, cardiovascular disorders |
| 01/19/2006 | US20060014678 adminsteration of Peptide YY and glucagons-like peptide-1( GLP-1) or agonists to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism |
| 01/19/2006 | US20060014677 Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| 01/19/2006 | US20060014676 Melanocortin receptor-specific hexapeptides |
| 01/19/2006 | US20060014675 Methods for preparing internally constrained peptides and peptidomimetics |
| 01/19/2006 | US20060014674 Methods for preparing purified lipopeptides |
| 01/19/2006 | US20060014673 Kappa-A conopeptides and uses therefor |
| 01/19/2006 | US20060014672 Tumor specific oligosaccharide epitopes and use thereof |
| 01/19/2006 | US20060014671 Hemoglobin solution packaged in an oxygen and water vapor impermeable flexible container with a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer for storage and preservation of deoxygenated hemoglobin solution |
| 01/19/2006 | US20060014670 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 01/19/2006 | US20060014669 Method for treating cancer and increasing hematocrit levels |
| 01/19/2006 | US20060014668 Antigenic gp 100 compounds for therapy and diagnosis and methods of using same |
| 01/19/2006 | US20060014667 Peptide composition and method for delivering substances into the cytosol of cells |
| 01/19/2006 | US20060014666 Water-solubility macromolecule conjugate with interferon; polyoxyethylene glycol, polyoxypropylene glycol or copolymers; one end group having a glucose attached, the other an interferon; long physiological cycle half-life; bioavailability; binds to asialoglycoprotein receptors on liver; hepititis B/C |
| 01/19/2006 | US20060014665 Therapeutic agent |
| 01/19/2006 | US20060014277 Novel human kielin-like proteins and polynucleotides encoding the same |
| 01/19/2006 | US20060014254 Albumin fusion proteins |
| 01/19/2006 | US20060014253 Lamprey GnRH-III polypeptides and methods of making thereof |
| 01/19/2006 | US20060014252 Flk-1 binding protein |
| 01/19/2006 | US20060014249 Human G-protein coupled receptor |
| 01/19/2006 | US20060014246 Canine cold- and menthol-sensitive receptor 1 |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014241 Extended glucagon-like peptide-1 analogs |
| 01/19/2006 | US20060014222 Antibodies |
| 01/19/2006 | US20060014218 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1) |
| 01/19/2006 | US20060014204 Methods of inducing formation of functional and organized lymphatic vessels |
| 01/19/2006 | US20060014201 Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| 01/19/2006 | US20060014194 Melanocortin receptor-specific hexapeptides |
| 01/19/2006 | US20060014180 Human phosphatase RET31, and variants thereof |
| 01/19/2006 | US20060014173 PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use |
| 01/19/2006 | US20060014158 Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems |
| 01/19/2006 | US20060014147 Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| 01/19/2006 | US20060014139 Which comprises three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41; inhibits infection of cells; drug screening; gene therapy |
| 01/19/2006 | US20060013889 Colostrum-based treatment for irritable bowel syndrome |
| 01/19/2006 | US20060013888 using monoterpenes such as limonene; encapsulation; soft capsules |
| 01/19/2006 | US20060013883 Poloxamer and poloxamine compositions for nucleic acid delivery |
| 01/19/2006 | US20060013879 Gel composition and methods |
| 01/19/2006 | US20060013877 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 01/19/2006 | US20060013860 Anticancer agents; side effect reduction |
| 01/19/2006 | US20060013832 Methods for treating HIV infected subjects |
| 01/19/2006 | US20060013820 Antigen delivery vectors and constructs |
| 01/19/2006 | US20060013817 identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. |
| 01/19/2006 | US20060013816 IgG4 constant region; Fab' fragment; antibody or antigen binding fragment inhibits binding of A2 or cA2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha |
| 01/19/2006 | US20060013813 Proteins and nucleic acids encoding same |
| 01/19/2006 | US20060013812 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 01/19/2006 | US20060013811 Methods of treating IgE-associated disorders and compositions for use therein |
| 01/19/2006 | US20060013808 Treatment for asthma |
| 01/19/2006 | US20060013807 Rapidly disintegrating enzyme-containing solid oral dosage compositions |
| 01/19/2006 | US20060013805 Transgenic circulating endothelial cells |
| 01/19/2006 | US20060013802 Pumping device equipped with catheter; directly delivering interleukin 10 signal transduction modifying agent to cerebrospinal fluid and/or brain tissue |
| 01/19/2006 | US20060013801 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity |